Updated Chinese Myeloma Guidelines Now Recommend Freelite® By Name!
The new and revised 2015 Chinese Myeloma Guidelines now combine all the guidelines from the World Health Organization (WHO), National Comprehensive Cancer Network (NCCN) and International Myeloma Working Group (IMWG). They recommend Freelite by name for free light chain measurement: “The technique from The Binding Site Group (Birmingham, UK) is recommended,”
Serum free light chain assays were first recommended in the 2013 Chinese Myeloma Guidelines for diagnosis and monitoring response to treatment and disease progression in Multiple Myeloma.
Binding Site CEO, Charles de Rohan, commented “This is another exciting step for the Binding Site, as we continue to extend the reach of Freelite testing for myeloma sufferers globally. This endorsement by the Chinese Opinion Leaders provides further evidence of Freelite’s utility and its value to the clinicians who manage the identification and treatment of myeloma patients.”
Freelite is a rapid, quantitative assay that measures kappa (κ) and lambda (λ) immunoglobulin free light chains in Multiple Myeloma. These values can be expressed as a κ/λ free light chain ratio.
Download your free copy of the Chinese Myeloma Guidelines (in Chinese)